NZ
CA
UK
US
AU
IND
Last update at
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Tue 22 Apr 25, 08:17 AMIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Tue 15 Apr 25, 10:37 PMAll You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Mon 14 Apr 25, 04:00 PMTelix Announces Cardinal Health for Gozellix Commercial Distribution
Tue 08 Apr 25, 10:30 AMTelix Appoints Paul Schaffer as Chief Technology Officer
Sun 06 Apr 25, 11:09 PMAnne Whitaker Appointed as Non-Executive Director
Thu 03 Apr 25, 10:13 PMARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
Tue 01 Apr 25, 12:49 PMFDA Approves New Prostate Cancer Imaging Agent Gozellix®
Fri 21 Mar 25, 10:30 AM| Breakdown |
|---|
| Breakdown |
|---|
| Breakdown |
|---|
Sector: Industry:
| Company | Change () | Price () | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) |
|---|
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...